$1.57
Regulus Therapeutics is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 31 staff and has a trailing 12-month revenue of around $5 million.
Our top picks for where to buy Regulus Therapeutics stock
How to buy Regulus Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – RGLS. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Regulus Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Regulus Therapeutics stock price (NASDAQ: RGLS)
Use our graph to track the performance of RGLS stocks over time.Regulus Therapeutics shares at a glance
Latest market close | $1.60 |
---|---|
52-week range | $1.08 - $3.00 |
50-day moving average | $1.73 |
200-day moving average | $1.81 |
Wall St. target price | $10.33 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.20 |
Is it a good time to buy Regulus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Regulus Therapeutics price performance over time
Historical closes compared with the close of $1.6 from 2024-09-04
1 week (2024-08-29) | -3.03% |
---|---|
1 month (2024-08-05) | 5.96% |
3 months (2024-06-05) | -32.49% |
6 months (2024-03-05) | 8.11% |
1 year (2023-09-05) | -4.19% |
---|---|
2 years (2022-09-02) | 12.68% |
3 years (2021-09-03) | 105.13% |
5 years (2019-09-05) | 166.67% |
Regulus Therapeutics financials
Revenue TTM | $5 million |
---|---|
Gross profit TTM | $-18,410,000 |
Return on assets TTM | -31.73% |
Return on equity TTM | -53.55% |
Profit margin | 0% |
Book value | $1.50 |
Market Capitalization | $110 million |
TTM: trailing 12 months
Regulus Therapeutics share dividends
We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.
Have Regulus Therapeutics's shares ever split?
Regulus Therapeutics's shares were split on a 1:10 basis on 28 June 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.
Regulus Therapeutics share price volatility
Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $1.08 up to $3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.622. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Regulus Therapeutics overview
Regulus Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .
Frequently asked questions
What percentage of Regulus Therapeutics is owned by insiders or institutions?Currently 1.69% of Regulus Therapeutics shares are held by insiders and 95.317% by institutions. How many people work for Regulus Therapeutics?
Latest data suggests 31 work at Regulus Therapeutics. When does the fiscal year end for Regulus Therapeutics?
Regulus Therapeutics's fiscal year ends in December. Where is Regulus Therapeutics based?
Regulus Therapeutics's address is: 4224 Campus Point Court, San Diego, CA, United States, 92121 What is Regulus Therapeutics's ISIN number?
Regulus Therapeutics's international securities identification number is: US75915K3095 What is Regulus Therapeutics's CUSIP number?
Regulus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 75915K200
More guides on Finder
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
6 stocks like Nvidia you need to consider
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Public vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question